1. Clomipramine concentration as a predictor of delayed response: a naturalistic study

   • M. Gex-Fabry
   • A. E. Balant-Gorgia
   • L. P. Balant

   CLINICAL TRIALS Pages: 895 - 902

2. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment

   • T. Korhonen
   • M. L. Hannuksela
   • M. J. Savolainen

   PHARMACODYNAMICS Pages: 903 - 910

3. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men

   • P. Lijnen
   • R. Fagard
   • V. Petrov

   PHARMACODYNAMICS Pages: 911 - 915

4. Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter A double-blind, randomized, placebo-controlled trial

   • M. Villardell
   • D. Sabat
   • C. Vallvé

   PHARMACODYNAMICS Pages: 917 - 921

5. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects

   • C. Laroudie
   • D. E. Salazar
   • J.-P. Decourt

   PHARMACOKINETICS AND DISPOSITION Pages: 923 - 928

6. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers

   • R. A. Faaij
   • N. Srivastava
   • A. F. Cohen

   PHARMACOKINETICS AND DISPOSITION Pages: 929 - 935

7. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment

   • K. Abou-Hatab
   • L. S. Nixon
   • K. W. Woodhouse

   PHARMACOKINETICS AND DISPOSITION Pages: 937 - 941

8. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance

   • O. Spigset
   • S. Hägg
   • R. Dahlqvist

   PHARMACOKINETICS AND DISPOSITION Pages: 943 - 946

9. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

   • A. Hemeryck
   • C. De Vriendt
   • F. M. Belpaire

   PHARMACOKINETICS AND DISPOSITION Pages: 947 - 951

10. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function

    • H. Buter
    • G. Y. Navis
    • P. E. de Jong

    PHARMACOKINETICS AND DISPOSITION Pages: 953 - 958

11. Suspected adverse drug events requiring emergency department visits or hospital admissions

    • R. Raschetti
    • M. Morgutti
    • C. La Guidara

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 959 - 963

12. Use of laxatives in institutions for the mentally retarded

    • M. Van Winckel
    • R. Vander Stichele
    • M. Bogaert

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 965 - 969